Kinnov Therapeutics
Developer of KT-110, an oral drug candidate for alcohol use disorder, in clinical development for addiction treatment
Highlights
- New on EvolcAdded 2026-11-14
About Kinnov Therapeutics
Kinnov Therapeutics develops KT-110, a first-in-class pharmaceutical composition combining prazosin and cyproheptadine for the treatment of addiction. The company reports that KT-110 completed a phase 2 proof-of-concept trial in alcohol use disorder, with a phase 3 study being designed.
It was created in 2015 as a spin-off from Greenpharma and Key-Obs, and is based in Orléans, France.
Kinnov's website lists Horizon 2020 funding for its alcohol use disorder projects and a patented once-daily galenic form of KT-110 under evaluation with the French regulator ANSM.
Product: KT-110, a first-in-class oral combination of prazosin and cyproheptadine for alcohol use disorder, in phase 2 completed and phase 3 design.
Jobs at Kinnov Therapeutics
Leadership
- Philippe BERNARD · Kinnov Therapeutics CEOSource: company website
More biotech & pharma companies
Kreatis
In silico toxicology and ecotoxicology predictions for chemical regulatory dossiers, used in place of animal testingNew on EvolcLa Fabrique Vegetale
Develops plant-based cosmetic and fragrance ingredients for cosmetics and perfumery manufacturersNew on EvolcLaboratoires Delbert
Preserves and markets essential medicines for patients and healthcare professionals, with a focus on critical and rare-disease needsLaboratoires Kol
Makes treatments available to patients with rare diseases and unmet needs, with a focus on ophthalmology and pediatricsNew on EvolcLaboratoires Majorelle
Pharmaceutical treatments, medical devices and family health products for patients and healthcare professionalsLaboratoires Thea
Develops ophthalmic medicines and eye-care products for healthcare professionals and their patients
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Backend
- PHPHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-powered-by
- Response headerx-powered-by
- Response headerx-powered-by
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Website resourcedeclared script/iframe or software asset
Hosting
- nginxHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.